Impax Laboratories Inc. v. Lannett Holdings Inc., 17-2020 (Fed. Cir. 2018)
- Jul 2 2018 |
- Category: CAFC Updates
Lannett appeals from the District Court’s decision concluding that certain claims of U.S. Patent 6,760,237 and U.S. Patent 7,220,767 relating to formulations of zolmitriptan for intranasal administration were not shown to be invalid, entering judgment in favor of Impax, and entering an injunction against Lannett. Finding no clear error in the District Court’s obviousness conclusion (including secondary consideration analysis), the CAFC affirms.